

# Contents

Foreword .....	iii
Preface .....	xiii
Acknowledgements.....	xv
Main source books.....	xv
Commonly used abbreviations .....	xvi
Introduction.....	1
The National Immunisation Schedule 2006 .....	1
Changes in the Immunisation Handbook 2006 .....	3
Other recommendations.....	4
Safe delivery and assessing contraindications.....	4
Immunisation programme changes.....	5
Immunisation coverage in New Zealand .....	6
<b>Key points .....</b>	<b>12</b>
Hepatitis B key points .....	12
Diphtheria key points .....	14
Tetanus key points .....	16
Pertussis key points .....	18
<i>Haemophilus influenzae</i> type b (Hib) key points .....	20
Poliomyelitis (Polio) key points .....	22
Measles key points .....	24
Mumps key points .....	26
Rubella key points .....	28
Tuberculosis (TB) key points .....	30
Influenza key points .....	32
Hepatitis A key points .....	34
Meningococcal Invasive Disease key points.....	35
Pneumococcal Disease key points .....	37
Varicella (chickenpox) key points .....	41
<b>General Considerations.....</b>	<b>42</b>
1.1 Immunity.....	42

1.2 Principles of immunisation .....	43
1.3 National Immunisation Schedule .....	45
1.4 Notifiable diseases in New Zealand .....	51
1.5 Vaccine types and composition.....	60
1.6 Adolescent and adult vaccination .....	64
1.7 Special groups: immigration, work and pregnancy .....	66
1.8 Special risk groups: medical conditions .....	67
1.9 Contraindications .....	76
References .....	79
<b>2 Processes for Safe Immunisation.....</b>	<b>80</b>
2.1 Vaccinator training .....	80
2.2 Informed consent .....	81
2.3 Vaccine administration .....	85
2.4 Expected responses and adverse events following immunisation (AEFI) .	103
2.5 Vaccine storage, transportation and disposal .....	113
<b>3 Hepatitis B .....</b>	<b>126</b>
3.1 Introduction .....	126
3.2 The illness .....	126
3.3 Epidemiology .....	128
3.4 Vaccines .....	131
3.5 Recommended immunisation schedule .....	133
3.6 Expected responses and adverse events following immunisation (AEFI) .	138
3.7 Contraindications .....	139
3.8 Control measures.....	139
References .....	140
<b>4 Diphtheria.....</b>	<b>142</b>
4.1 Introduction .....	142
4.2 The illness .....	142
4.3 Epidemiology .....	143
4.4 Vaccines .....	146
4.5 Recommended immunisation schedule .....	147
4.6 Expected responses and adverse events following immunisation (AEFI) .	149

4.7	Contraindications .....	149
4.8	Control measures.....	149
	References .....	151
<b>5</b>	<b>Tetanus .....</b>	<b>152</b>
5.1	Introduction .....	152
5.2	The illness .....	152
5.3	Epidemiology .....	152
5.4	Vaccines .....	155
5.5	Recommended immunisation schedule .....	155
5.6	Expected responses and adverse events following immunisation (AEFI) .	159
5.7	Contraindications .....	160
5.8	Control measures.....	160
	References .....	160
<b>6</b>	<b>Pertussis (Whooping Cough) .....</b>	<b>161</b>
6.1	Introduction .....	161
6.2	The illness .....	161
6.3	Epidemiology .....	162
6.4	Vaccines .....	170
6.5	Recommended immunisation schedule .....	171
6.6	Expected responses and adverse events following immunisation (AEFI) .	172
6.7	Contraindications and precautions .....	175
6.8	Control measures.....	176
	References .....	178
<b>7</b>	<b><i>Haemophilus influenzae</i> type b (Hib) .....</b>	<b>183</b>
7.1	Introduction .....	183
7.2	The illness .....	183
7.3	Epidemiology .....	184
7.4	Vaccines .....	187
7.5	Recommended immunisation schedule .....	188
7.6	Expected responses and adverse events following immunisation (AEFI) .	190
7.7	Contraindications .....	190

7.8 Control measures.....	191
References .....	193
<b>8 Poliomyelitis.....</b>	<b>194</b>
8.1 Introduction .....	194
8.2 The illness .....	195
8.3 Epidemiology .....	196
8.4 Vaccines.....	200
8.5 Recommended immunisation schedule .....	202
8.6 Expected responses and adverse events following immunisation (AEFI) .	203
8.7 Contraindications .....	203
8.8 Control measures.....	204
References .....	205
<b>9 Measles .....</b>	<b>206</b>
9.1 Introduction .....	206
9.2 The illness .....	206
9.3 Epidemiology .....	207
9.4 Vaccines.....	212
9.5 Recommended immunisation schedule .....	213
9.6 Expected responses and adverse events following immunisation (AEFI) .	215
9.7 Contraindications .....	218
9.8 Control measures.....	219
References .....	222
<b>10 Mumps .....</b>	<b>225</b>
10.1 Introduction .....	225
10.2 The illness.....	225
10.3 Epidemiology .....	225
10.4 Vaccines.....	227
10.5 Recommended immunisation schedule .....	227
10.6 Expected responses and adverse events following immunisation (AEFI) .	227
10.7 Contraindications .....	228
10.8 Control measures .....	228
References .....	229

<b>11 Rubella</b> .....	<b>230</b>
11.1 Introduction .....	230
11.2 The illness.....	230
11.3 Epidemiology .....	231
11.4 Vaccines.....	233
11.5 Recommended immunisation schedule .....	234
11.6 Expected responses and adverse events following immunisation (AEFI) .	237
11.7 Contraindications .....	237
11.8 Control measures .....	238
References .....	239
<b>12 Tuberculosis</b> .....	<b>241</b>
12.1 Introduction .....	241
12.2 The illness.....	241
12.3 Epidemiology .....	242
12.4 Vaccines.....	246
12.5 Recommended immunisation schedule .....	247
12.6 Expected responses and adverse events following immunisation (AEFI).	250
12.7 Contraindications .....	252
12.8 Control measures .....	252
References .....	253
<b>13 Influenza</b> .....	<b>255</b>
13.1 Introduction .....	255
13.2 The illness.....	255
13.3 Epidemiology .....	257
13.4 Vaccine.....	261
13.5 Recommended immunisation schedule .....	263
13.6 Expected responses and adverse events following immunisation (AEFI).	266
13.7 Contraindications .....	268
13.8 Control measures .....	268
References .....	271
<b>14 Hepatitis A</b> .....	<b>274</b>
14.1 Introduction .....	274

14.2 The illness.....	274
14.3 Epidemiology .....	275
14.4 Vaccines.....	276
14.5 Recommended immunisation schedule .....	280
14.6 Expected responses and adverse events following immunisation (AEFI) ..	282
14.7 Contraindications .....	282
14.8 Control measures and passive immunisation .....	282
References .....	284
<b>15 Meningococcal Invasive Disease.....</b>	<b>285</b>
15.1 Introduction .....	285
15.2 The illness.....	285
15.3 Epidemiology .....	286
15.4 Vaccines.....	290
15.4A Meningococcal polysaccharide vaccines: group A, C, Y and W135 vaccines.....	292
15.4B Protein conjugate meningococcal group C vaccines .....	293
15.4C Group B meningococcal vaccines.....	296
15.5 Recommended immunisation schedule .....	299
15.5A Recommended immunisation: group A, C, Y, W135 polysaccharide vaccines.....	299
15.5B Recommended immunisation: group C meningococcal conjugate vaccine .....	301
15.5C Special programme for MeNZB™ vaccine: schedule recommendations and funding .....	301
15.6 Expected responses and adverse events following immunisation (AEFI)..	302
15.6A Meningococcal polysaccharide vaccines .....	302
15.6B Group C meningococcal conjugate vaccine .....	303
15.6C MeNZB™.....	303
15.7 Contraindications .....	306
15.7A Meningococcal polysaccharide vaccines contraindications .....	306
15.7B Group C meningococcal conjugate vaccine contraindications.....	306
15.7C MeNZB™ contraindications.....	306
15.8 Control measures .....	306
References .....	308

<b>16 Pneumococcal Disease .....</b>	<b>312</b>
16.1 Introduction .....	312
16.2 The illness.....	312
16.3 Epidemiology .....	312
16.4 Vaccines.....	315
16.4A Seven-valent conjugate vaccine (PCV7).....	315
16.4B Pneumococcal polysaccharide 23-valent vaccine (23PPV).....	318
16.5 Vaccine recommendations .....	321
16.5A Seven-valent conjugate vaccine recommendations for children .....	322
16.5B Pneumococcal polysaccharide 23-valent vaccine recommendations for children and adults .....	326
16.6 Expected responses and adverse events following immunisation (AEFI). 328	
16.6A Seven-valent conjugate vaccine (PCV7).....	328
16.6B Pneumococcal polysaccharide 23-valent vaccine (23PPV) .....	329
16.7 Contraindications to pneumococcal conjugate and polysaccharide vaccines .....	329
16.8 Passive immunisation and prophylaxis.....	329
References .....	330
<b>17 Varicella (Chickenpox and Shingles) .....</b>	<b>333</b>
17.1 Introduction .....	333
17.2 The illness.....	333
17.3 Epidemiology .....	334
17.4 Vaccines.....	336
17.5 Recommended immunisation schedule .....	338
17.6 Expected responses and adverse events following immunisation (AEFI). 340	
17.7 Contraindications .....	341
17.8 Control measures .....	341
References .....	344
<b>18 Passive Immunisation .....</b>	<b>346</b>
18.1 Introduction .....	346
18.2 Preparations available in New Zealand .....	346
18.3 Indications for use.....	347
18.4 Storage and administration .....	348

18.5 Duration of effect.....	348
18.6 Expected responses and adverse reactions.....	348
18.7 Precautions and contraindications.....	349
Reference .....	350
<b>19 New Vaccines .....</b>	<b>351</b>
19.1 Human papilloma virus .....	351
19.2 Rotavirus .....	356
References .....	357
<b>20 Vaccination Questions and Concerns .....</b>	<b>359</b>
20.1 Some commonly asked questions.....	359
20.2 Responding to concerns about immunisation .....	362
20.3 Lessons from the past .....	381
20.4 Conclusion .....	383
References .....	384
<b>Appendices.....</b>	<b>389</b>
1 The History of Immunisation in New Zealand.....	389
2 Immunisation Catch Up Schedules.....	394
3 Immunisation Standards 2006.....	397
4 Authorisation as an Independent Vaccinator.....	408
5 Immunisation Certificate .....	415
6 Vaccine Presentation, Preparation and Disposal .....	417
7 Medicines Act 1981, Section 47 .....	420
8 Hepatitis B Antibody Levels in Infants .....	421
9 Meningococcal Invasive Disease .....	422
10 Management of Exposure to Varicella During Pregnancy and Care of the Newborn .....	428
11 Websites .....	431

# Preface

Welcome to the *Immunisation Handbook 2006*.

This Handbook provides information on the National Immunisation Schedule 2006 for children and recommendations for adult immunisation. There is information on the immunisation programme and on vaccines that may be available and used in New Zealand. Since the last edition of the Handbook, New Zealand health professionals have delivered a nation-wide Meningococcal B Immunisation Programme, offered to all children and young adults age 0–19 years. The National Immunisation Register was used for the Meningococcal B Immunisation Programme and is now recording immunisation information on all infants born in New Zealand, with parental consent. We shall now be able to record children's immunisations and follow-up children who do not receive immunisation and measure coverage.

The new National Immunisation Schedule (Schedule) began on 1 February 2006, and all children will transfer to the new Schedule. In 2006, children at age 11 years will be offered the dTap-IPV vaccine (tetanus, adult dose of diphtheria and adult dose of pertussis vaccines and inactivated polio vaccine). This pertussis containing vaccine will offer protection to adolescents against pertussis. At the age of 15 months MMR (measles, mumps, and rubella vaccine) and Hib vaccine will be given. The Meningococcal B Immunisation Programme will continue for infants and the programme will be reviewed regularly until the vaccine can be discontinued. From 2006 pneumococcal vaccine is available for a small group of children at high risk of pneumococcal disease and for adults or children pre- or post-splenectomy.


The Ministry of Health's Immunisation Technical Working Group (ITWG) provided advice on the National Immunisation Schedule 2006, and have re-written this Handbook. The ITWG was assisted by a number of health professionals and individuals who all contributed their expertise to chapter writing or peer review of the chapters.

Because of the rapid developments and availability of new vaccines, the Schedule will be reviewed, though not necessarily changed, every two years. This will allow New Zealand children to receive the most appropriate, safe and effective vaccines.


# The ITWG Handbook authors




*Dr Tim Blackmore*  
Infectious Diseases Physician and  
Microbiologist




*Associate Professor Glenn Buchan*  
Associate Professor in Immunology  
and Microbiology




*Associate Professor Cameron Grant*  
Paediatrician and Associate Professor  
in Paediatrics




*Professor Keith Grimwood*  
Professor of Paediatrics and  
Child Health




*Professor Diana Lennon*  
Professor Community Paediatrics



*Professor David Murdoch*  
Clinical Microbiologist and Infectious  
Diseases Physician



*Jillian Pierce*  
Registered Nurse



*Dr Stewart Reid*  
General Practitioner



*Dr Alison Roberts*  
Manager Communicable Diseases  
and Immunisation

# Acknowledgements

The Ministry of Health appreciates the time and commitment of those involved in the updating and rewriting of the *Immunisation Handbook 2006*.

Those the Ministry wishes to specifically acknowledge are: Martin Bonné, Lester Calder, Stephen Chambers, Vikki Cheer, Kitty Croxson, Janey Daly, Natalie Desmond, Jason Eberhart-Phillips, Margaret Estcourt, Lance Goodall, Fiona Grant, Simon Hoare, David Holland, John Holmes, Joan Ingram, Lance Jennings, Mark Jones, Hazel Lewis, Christine Lloyd, Caroline McElnay, Jill McKenzie, Chris Moyes, Diana Murfitt, Pamela Raynel, Loretta Roberts, Ann Shaw, Jan Sinclair, Marjorie Squire, Grant Storey, Michael Tatley, Mark Thomas, Nikki Turner, Lesley Voss, and Elizabeth Wilson.

## Main source books

*Adis International*, MIMS. Adis International.

American Academy of Pediatrics. 2003. In: L K Pickering (ed) *Red Book: Report of the Committee on Infectious Diseases* (26th edition). Elk Grove Village, IL: American Academy of Pediatrics.

Heymann DL (ed). 2004. *Control of Communicable Diseases Manual* (18th edition). Washington: American Public Health Association.

Information on New Zealand epidemiology is sourced from data collated by the Institute of Environmental Science and Research (ESR), on behalf of the Ministry of Health, or from the New Zealand Health Information Services (NZHIS).

Ministry of Health. Revised 2005. *Well Child Tamariki Ora Health Book*. Wellington: Ministry of Health.

Ministry of Health. 1998. *Communicable Diseases Control Manual*. Wellington: Ministry of Health.

Ministry of Health. 2003. *Guidelines for Tuberculosis Control 2003*. Wellington: Ministry of Health.

Ministry of Health. 1996. *Technical Guidelines for Tuberculin Testing and BCG Vaccination 1996*. Wellington: Ministry of Health.

Ministry of Health. 1996. *Health Advice for Overseas Travellers*. Wellington: Ministry of Health.

National Health and Medical Research Council. 2003. *The Australian Immunisation Handbook* (8th edition). Canberra. Australian Government Publishing Service.

SA Plotkin, WA Orenstein (eds) 2004. *Vaccines* (4th edition). Philadelphia: WB Saunders Company.

# Commonly used abbreviations

ACC	Accident Compensation Corporation
AEFI	adverse event following immunisation
AFP	acute flaccid paralysis
AIDS	acquired immunodeficiency syndrome
BCG	Bacillus Calmette-Guérin vaccine
BSE	bovine spongiform encephalopathy
CARM	Centre for Adverse Reactions Monitoring
CRS	congenital rubella syndrome
CSF	cerebrospinal fluid
DHB	district health board
DNA	deoxyribonucleic acid
DT	diphtheria tetanus vaccine
DTaP	diphtheria, tetanus and acellular pertussis vaccine
DTaP/Hib	diphtheria, tetanus, acellular pertussis and <i>Haemophilus influenzae</i> type b vaccine
DTaP-IPV	diphtheria, tetanus, acellular pertussis and inactivated polio vaccine
dTap-IPV	adult dose diphtheria, tetanus, acellular pertussis and inactivated polio vaccine
DTwP	diphtheria, tetanus and whole cell pertussis vaccine
DTwPH	diphtheria, tetanus, whole cell pertussis and <i>Haemophilus influenzae</i> type b vaccine
ESR	Institute of Environmental Science and Research
GBS	Guillain-Barré Syndrome
HAV	hepatitis A virus
Hep B	hepatitis B vaccine
HBIG	hepatitis B immunoglobulin
HBsAg	hepatitis B surface antigen
HHE	hypotonic, hyporesponsive episode
Hib	<i>Haemophilus influenzae</i> type b
HIV	human immunodeficiency virus
HPV	human papilloma virus
IG	immunoglobulin

IM	intramuscular
IMAC	Immunisation Advisory Centre
IPV	inactivated polio vaccine
IV	intravenous
IVIG	intravenous immunoglobulin
LMC	lead maternity carer
MeNZB™	meningococcal B vaccine
MMR	measles, mumps and rubella vaccine
NIR	National Immunisation Register
NZPSU	New Zealand Paediatric Surveillance Unit
OMP	outer membrane protein
OPV	oral polio vaccine
PCR	polymerase chain reaction
PCV7	seven valent pneumococcal conjugate vaccine
PHO	primary health organisation
23PPV	23 valent pneumococcal polysaccharide vaccine
PRP	polyribosylribitol phosphate
RCT	randomised control trial
RIG	rabies immunoglobulin
SC	subcutaneous
SIDS	sudden infant death syndrome or cot death
Td	adult tetanus diphtheria vaccine
TIG	tetanus immunoglobulin
TT	tetanus toxoid
TB	tuberculosis
UK	United Kingdom
US	United States of America
VAPP	vaccine associated paralytic poliomyelitis
vCJD	variant Creutzfeldt-Jakob disease
VZV	varicella zoster virus
WHO	World Health Organization
ZIG	varicella-zoster immunoglobulin